ArticleFrontiers in immunology2021
Antibody Subclass and Glycosylation Shift Following Effective TB Treatment.
Open access · goldAbstract read
In one paragraph
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
2.2field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 48 citations in OpenAlex.
- Nucleocapsid-specific antibody function is associated with therapeutic benefits from COVID-19 convalescent plasma therapy.Cell reports. Medicine · 2022Trial
- An Fc Receptor and IgA Functional Signature Identifies TB Disease in Children Living With HIV.Journal of the Pediatric Infectious Diseases Society · 2026Article
- Tuberculosis treatment and cytotoxic immune signatures: a longitudinal study.Journal of clinical tuberculosis and other mycobacterial diseases · 2026Article
- Glycosylation profile ofiScience · 2026Article
- The study of immunological markers in tuberculosis across animal models and its translation to human research.Lab animal · 2026Review
- Modified Anti-PstS1 Bi-specific antibodies unlock potent protection against tuberculosis.PLoS pathogens · 2026Article
- Antibodies in tuberculosis: functional capacity as key determinant.Infection and immunity · 2026Review
- ESAT-6 and CFP-10 reactive IgG in patients with tuberculosis inhibits intracellular bacteria.Cell reports · 2025Article
- N-Glycosylation of Antibodies: Biological Effects During Infections and Therapeutic Applications.Antibodies (Basel, Switzerland) · 2025Review
- Article
- Glycosylation in kidney diseases.Precision clinical medicine · 2025Review
- Infection with Mycobacterium tuberculosis alters the antibody response to HIV-1.PLoS pathogens · 2025Article
- Sera contributing to mycobacterial growth restrictioniScience · 2025Article
- Testing the Antigenic Potential of Transmembrane Proteins To Develop a Thermostable Tuberculosis MOF-Liposomal Vaccine.ACS infectious diseases · 2025Article
- A flexible systems analysis pipeline for elucidating spatial relationships in the tumor microenvironment linked with cellular phenotypes and patient-level features.Frontiers in immunology · 2025Article
- Different antibody isotypes against tuberculosis: what we know and what we need to know.Frontiers in immunology · 2025Review
- Spatial colocalization and combined survival benefit of natural killer and CD8 T cells despite profound MHC class I loss in non-small cell lung cancer.Journal for immunotherapy of cancer · 2024Article
- Antigen specificity shapes antibody functions in tuberculosis.bioRxiv : the preprint server for biology · 2024Article
- Spatial colocalization and combined survival benefit of natural killer and CD8 T cells despite profound MHC class I loss in non-small cell lung cancer.bioRxiv : the preprint server for biology · 2024Article
- B cell heterogeneity in human tuberculosis highlights compartment-specific phenotype and functional roles.Communications biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 8 institutions in 3 countries.
Patricia S GraceRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA, United States.
Sepideh DolatshahiDepartment of Biomedical Engineering, University of Virginia, Charlottesville, VA, United States.
Lenette L LuDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, United States.
Adam CainRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA, United States.
Fabrizio PalmieriClinical Department, National Institute for Infectious Diseases (INMI), IRCCS L. Spallanzani, Rome, Italy.
Linda PetroneDepartment of Epidemiology and Preclinical Research, National Institute for Infectious Diseases IRCCS (INMI) L. Spallanzani, Rome, Italy.
Sarah M FortuneDepartment of Immunology and Infectious Disease, Harvard School of Public Health, Boston, MA, United States.
Tom H M OttenhoffDepartment of Infectious Disease, Leiden University Medical Center, Leiden, Netherlands.
Douglas A LauffenburgerDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, United States.
Delia GolettiDepartment of Epidemiology and Preclinical Research, National Institute for Infectious Diseases IRCCS (INMI) L. Spallanzani, Rome, Italy.
Simone A JoostenDepartment of Infectious Disease, Leiden University Medical Center, Leiden, Netherlands.
Galit AlterRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA, United States.
Ragon Institute of MGH, MIT and Harvard · USIstituti di Ricovero e Cura a Carattere Scientifico · ITLeiden University Medical Center · NLHarvard University · USIstituto Nazionale per le Malattie Infettive Lazzaro Spallanzani · ITMassachusetts Institute of Technology · USThe University of Texas Southwestern Medical Center · USUniversity of Virginia · US
Funding
INFECTIOUS DISEASE AND BASIC MICROBIOLOGICAL MECHANISMST32AI007061 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Marcia B Goldberg · 1985 to 2026
$12.1MAntibody Mediated Mechanisms of Immune Modulation in TuberculosisK08AI130357 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI LU, LENETTE · 2017 to 2021
$984kNIAID NIH HHS K08 AI130357NIAID NIH HHS T32 AI007061
Abstract
With an estimated 25% of the global population infected with
Indexed as
Antibodies, BacterialAntigens, BacterialAntitubercular AgentsFemaleGlycosylationHost-Pathogen InteractionsHumansImmunoglobulin Fc FragmentsImmunoglobulin GKiller Cells, NaturalLatent TuberculosisMaleMycobacterium tuberculosisNeutrophilsPhagocytosisPolysaccharidesAntibodies, BacterialAntigens, BacterialAntitubercular AgentsImmunoglobulin Fc FragmentsImmunoglobulin GPolysaccharidesantibodiesFc-glycosylationIgG4TB therapytuberculosis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.